View Our Facilities
In The News
BioCytics Partners on NCInnovation-Funded Vaccine Preservation Project
Inside UNC Charlotte – 5/14/25
BioCytics is proud to serve as a subawardee on a newly funded NCInnovation project led by Dr. Susan Trammell at UNC Charlotte. The research is one of 17 projects selected statewide and focuses on Light-Assisted Drying (LAD), a novel laser technology enabling room-temperature storage of vaccines and biologics by eliminating cold chain requirements. BioCytics will evaluate LAD’s potential to preserve cell therapy reagents, antibodies, and biospecimens, with proof-of-concept work using our GMP-grade materials and IRB-approved human samples.
AABB-Accredited Facility Biotherapies Services Spotlight Series February 2025: Carolina BioOncology Institute
AABB – 2/1/25
In 2005, John Powderly, MD, founded both CBOI and BioCytics as reflections of the same vision to deliver autologous immune cell therapies manufactured at the point of care for early phase clinical trials. He states that, “We believe the future of bespoke regenerative medicine depends upon regional human application labs as an efficient, affordable and accessible delivery system. Our recent AABB accreditation is another step closer to realizing our vision to enable future cellular immune cures for solid tumor cancer patients.”
National Minority Quality Forum’s announces a collaboration with Carolina BioOncology Institute
NMQF By Adjoa Kyerematen – 10/24/24
NMQF, Carolina BioOncology, and BioCytics are collaborating to create a national registry and biorepository for CSSI, collecting critical clinical, genetic, and demographic data from 20 communities. This biorepository will support research on cancer risk factors, driving logistical changes to ease the development and deployment of new detection technologies and precision treatments. De-identified data will be accessible to researchers, helping ensure that advancements in cancer care reach underserved communities. The findings will be used to improve local cancer care logistics, advancing the Cancer Moonshot’s goal of reducing cancer mortality in these populations by addressing bottlenecks through a data-driven approach.
